Curated News
By: NewsRamp Editorial Staff
May 04, 2026

NanoViricides' NV-387 Gets Orphan Drug Designation for Measles

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • NanoViricides' NV-387 gains FDA orphan drug status for measles, offering market exclusivity and cost advantages.
  • NV-387, a broad-spectrum antiviral, received orphan designation after demonstrating in vivo activity against measles.
  • This designation supports development of a treatment for rising global measles outbreaks, potentially saving lives.
  • NV-387 is a nanomaterial-based antiviral that also targets RSV, COVID, and monkeypox.

Impact - Why it Matters

This news matters because measles outbreaks are on the rise globally, and there are currently no approved antiviral treatments specifically for measles. The Orphan Drug Designation for NV-387 not only accelerates its development through FDA incentives but also highlights a potential breakthrough in addressing a serious public health threat. For investors, this designation could significantly enhance the drug's commercial prospects and the company's valuation. For patients, it offers hope for a targeted therapy against a dangerous and highly contagious disease.

Summary

NanoViricides, Inc. (NYSE American: NNVC) has announced that its clinical-stage antiviral drug NV-387 has been granted Orphan Drug Designation by the U.S. FDA for the treatment of measles. This designation provides potential incentives including tax credits, fee exemptions, and market exclusivity, supporting the regulatory advancement of NV-387. The drug is a broad-spectrum antiviral candidate that has demonstrated in vivo activity against measles and is being developed to address rising global outbreaks. The full press release can be accessed at https://ibn.fm/uIWWv.

NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral intended for treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. NV-387 has also shown effectiveness in animal models for Monkeypox, Smallpox, and Measles. The company's other advanced candidate, NV-HHV-1, targets Herpesvirus infections including HSV-1, HSV-2, VZV Shingles, and Chickenpox. NV-387 has successfully completed a Phase I human clinical trial with no reported adverse events, and the company is focused on advancing it into Phase II trials.

MissionIR, a specialized communications platform under the Dynamic Brand Portfolio @ IBN, assists IR firms in enhancing visibility for private and public companies. MissionIR provides access to a vast network of wire solutions via InvestorWire, article syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides' NV-387 Gets Orphan Drug Designation for Measles

blockchain registration record for this content.